Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3205-3210

  Presterl, Elisabeth ^a   Hajdu, Stefan ^a   Lassnigg, Andrea M ^a   Hirschl, Alexander M ^a   Holinka, Johannes ^a   Graninger, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; DAPTOMYCIN; FOSFOMYCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIUM ISOLATE; BIOFILM; CONCENTRATION RESPONSE; CONTROLLED STUDY; MICROTITER PLATE ASSAY; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; BIOFILMS; CEFTRIAXONE; DAPTOMYCIN; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN;

EID: 67749095088     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01628-08     Document Type: Article

References (39)

1. Amorena, B., E. Gracia, M. Monzon, J. Leiva, C. Oteiza, M. Perez, J. L. Alabart, and J. Hernandez-Yago. 1999. Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J. Antimicrob. Chemother. 44:43-55.
2. Benvenuto, M., D. P. Benziger, S. Yankelev, and G. Vigliani. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249.
3. Butt, M., D. Connolly, and G. Y. Lip. 2009. Drug-eluting stents: a comprehensive appraisal. Future Cardiol. 5:141-157.
4. Cerca, N., S. Martins, G. B. Pier, R. Oliveira, and J. Azeredo. 2005. The relationship between inhibition of bacterial adhesion to a solid surface by sub-MICs of antibiotics and subsequent development of a biofilm. Res. Microbiol. 156:650-655.
5. Ceri, H., M. E. Olson, C. Stremick, R. R. Read, D. Morck, and A. Buret. 1999. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771-1776.
6. Chen, M. C., H. W. Tsai, C. T. Liu, S. F. Peng, W. Y. Lai, S. J. Chen, Y. Chang, and H. W. Sung. 2009. A nanoscale drug-entrapment strategy for hydrogel-based systems for the delivery of poorly soluble drugs. Biomaterials 30:2102-2111.
7. Christensen, G. D., W. A. Simpson, J. J. Younger, L. M. Baddour, F. F. Barrett, D. M. Melton, and E. H. Beachey. 1985. Adherence of coagulasenegative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J. Clin. Microbiol. 22:996-1006.
8. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A7, 6th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Costerton, J. W., P. S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
10. Darouiche, R. O. 2004. Treatment of infections associated with surgical implants. N. Engl. J. Med. 350:1422-1429.
11. Donelli, G., and I. Francolini. 2001. Efficacy of antiadhesive, antibiotic and antiseptic coatings in preventing catheter-related infections: review. J. Chemother. 13:595-606.
12. Dunne, W. M., Jr. 1990. Effects of subinhibitory concentrations of vancomycin or cefamandole on biofilm production by coagulase-negative staphylococci. Antimicrob. Agents Chemother. 34:390-393.
13. Ehrlich, G. D., P. Stoodley, S. Kathju, Y. Zhao, B. R. McLeod, N. Balaban, F. Z. Hu, N. G. Sotereanos, J. W. Costerton, P. S. Stewart, J. C. Post, and Q. Lin. 2005. Engineering approaches for the detection and control of orthopaedic biofilm infections. Clin. Orthop. Relat. Res. 2005:59-66.
14. Foulds, G., P. Madsen, C. Cox, R. Shepard, and R. Johnson. 1991. Concentration of azithromycin in human prostatic tissue. Eur. J. Clin. Microbiol. Infect. Dis. 10:868-871.
15. Frossard, M., C. Joukhadar, B. M. Erovic, P. Dittrich, P. E. Mrass, H. M. Van, H. Burgmann, A. Georgopoulos, and M. Muller. 2000. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob. Agents Chemother. 44:2728-2732.
16. Gillis, R. J., and B. H. Iglewski. 2004. Azithromycin retards Pseudomonas aeruginosa biofilm formation. J. Clin. Microbiol. 42:5842-5845.
17. Hajdu, S., A. Lassnigg, W. Graninger, A. M. Hirschl, and E. Presterl. 24 April 2009. Effects of vancomycin, daptomycin, fosfomycin, tigecycline and ceftriaxone on Staphylococcus epidermidis biofilms. J. Orthop. Res. doi: 10.1002/jor.20902.
18. Hansen, C. R., T. Pressler, C. Koch, and N. Hoiby. 2005. Long-term azithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J. Cyst. Fibros. 4:35-40.
19. Hebert, C. K., R. E. Williams, R. S. Levy, and R. L. Barrack. 1996. Cost of treating an infected total knee replacement. Clin. Orthop. Relat. Res. 1996: 140-145.
20. -/- mice. Antimicrob. Agents Chemother. 51:3677-3687.
21. Huang, Y. T., C. H. Liao, L. J. Teng, and P. R. Hsueh. 2007. Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method. Antimicrob. Agents Chemother. 51:1570-1572.
22. Jefferson, K. K., D. A. Goldmann, and G. B. Pier. 2005. Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 49:2467-2473.
23. Kandemir, O., V. Oztuna, A. Milcan, A. Bayramoglu, H. H. Celik, C. Bayarslan, and A. Kaya. 2005. Clarithromycin destroys biofilms and enhances bactericidal agents in the treatment of Pseudomonas aeruginosa osteomyelitis. Clin. Orthop. Relat. Res. 2005:171-175.
24. Monzón, M., C. Oteiza, J. Leiva, M. Lamata, and B. Amorena. 2002. Biofilm testing of Staphylococcus epidermidis clinical isolates: low performance of vancomycin in relation to other antibiotics. Diagn. Microbiol. Infect. Dis. 44:319-324.
25. Olson, M. E., H. Ceri, D. W. Morck, A. G. Buret, and R. R. Read. 2002. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can. J. Vet. Res. 66:86-92.
26. Paterson, D. L. 1999. Reduced susceptibility of Staphylococcus aureus to vancomycin-a review of current knowledge. Commun. Dis. Intell. 23:69-73.
27. Pfaller, M. A., and L. A. Herwaldt. 1988. Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci. Clin. Microbiol. Rev. 1:281-299.
28. Pradeep, A. R., S. V. Sagar, and H. Daisy. 2008. Clinical and microbiologic effects of subgingivally delivered 0.5% azithromycin in the treatment of chronic periodontitis. J. Periodontol. 79:2125-2135.
29. Presterl, E., A. Lassnigg, B. Parschalk, F. Yassin, H. Adametz, and W. Graninger. 2005. Clinical behavior of implant infections due to Staphylococcus epidermidis. Int. J. Artif. Organs 28:1110-1118.
30. Presterl, E., M. Suchomel, M. Eder, S. Reichmann, A. Lassnigg, W. Graninger, and M. Rotter. 2007. Effects of alcohols, povidone-iodine and hydrogen peroxide on biofilms of Staphylococcus epidermidis. J. Antimicrob. Chemother. 60:417-420.
31. Presterl, E., S. Reichmann, S. Hajdu, J. Holinka, C. Kratzer, A. M. Hirschl, and W. Graninger. 2007. Azithromycin in combination with highly dosed ceftriaxone and tigecycline is most active against biofilms formed by Staphylococcus epidermidis isolated in implant infections, poster K2069. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
32. Raad, I., H. Hanna, Y. Jiang, T. Dvorak, R. Reitzel, G. Chaiban, R. Sherertz, and R. Hachem. 2007. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. 51: 1656-1660.
33. Saginur, R., M. StDenis, W. Ferris, S. D. Aaron, F. Chan, C. Lee, and K. Ramotar. 2006. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob. Agents Chemother. 50:55-61.
34. Sauermann, R., M. Rothenburger, W. Graninger, and C. Joukhadar. 2008. Daptomycin: a review 4 years after first approval. Pharmacology 81:79-91.
35. Schaad, H. J., M. Bento, D. P. Lew, and P. Vaudaux. 2006. Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection. BMC Infect. Dis. 6:74.
36. Schulin, T., and A. Voss. 2001. Coagulase-negative staphylococci as a cause of infections related to intravascular prosthetic devices: limitations of present therapy. Clin. Microbiol. Infect. 7(Suppl. 4):1-7.
37. Siegenthaler, M. P., J. Martin, and F. Beyersdorf. 2003. Mechanical circulatory assistance for acute and chronic heart failure: a review of current technology and clinical practice. J. Interv. Cardiol. 16:563-572.
38. Starner, T. D., J. D. Shrout, M. R. Parsek, P. C. Appelbaum, and G. Kim. 2008. Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and diminish established biofilms. Antimicrob. Agents Chemother. 52:137-145.
39. Yasuda, H., Y. Ajiki, T. Koga, and T. Yokota. 1994. Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis. Antimicrob. Agents Chemother. 38:138-141.